AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK120.28+0.86 (+0.72%) ▲|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM194.68+3.59 (+1.88%) ▲|QCOM176.50-5.48 (-3.01%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO612.55+2.55 (+0.42%) ▲|TMUS185.25+2.92 (+1.60%) ▲|TSLA361.18-4.26 (-1.17%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK120.28+0.86 (+0.72%) ▲|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM194.68+3.59 (+1.88%) ▲|QCOM176.50-5.48 (-3.01%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO612.55+2.55 (+0.42%) ▲|TMUS185.25+2.92 (+1.60%) ▲|TSLA361.18-4.26 (-1.17%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|
22.2 C
New York
Monday, September 14, 2026

Tag: statements

newssourceFORcompanyinformationcontent1releasesmarket

T1 Energy Advances $850 Million Planned 5 GW Solar Cell Plant

T1 Energy announces significant progress towards $850 million, 5 GW solar cell facility.

June 17, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NPWR

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NET Power, Inc. (NYSE: NPWR). ...

Vastrell Securities Strengthens Asia-Pacific Presence with Enhanced Localized Financial Services

DENVER, June 16, 2025 (GLOBE NEWSWIRE) -- Vastrell Securities (VRS), a global leader in comprehensive financial services and a wholly-owned subsidiary of Morgan Stanley, today announced an accelerated expansion plan across the Asia-Pacific region. This initiative reflects VRS’s long-term commitment to the region’s economic potential and its rapidly evolving investment demands.

GETCHELL GOLD CORP. ANNOUNCES CLOSING OF UPSIZED $4 MILLION FINANCING AND CONVERSION OF FIRST TRANCHE OF DEBENTURES

VANCOUVER, BC, June 16, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce that...

View. Click. Buy. PayPal Storefront Ads Expand Merchant Reach Across the Web

By turning ads into shoppable storefronts, merchants can bring commerce directly to consumers through advertising SAN JOSE, Calif., June 16, 2025 /PRNewswire/ -- PayPal is rewriting...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

CIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Civitas Resources, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Civitas Resources, Inc. (“Civitas” or “the Company”) (NYSE: CIVI) and certain of its officers.

IBTA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ibotta, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ibotta, Inc. (“Ibotta” or “the Company”) (NYSE: IBTA) and certain of its officers.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStatements

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers